Real-World Clinical Practice Use of 8-Week Glecaprevir/Pibrentasvir in Treatment-Naïve Patients with Compensated Cirrhosis

INTRODUCTION: More than 70 million people are estimated to be infected with hepatitis C virus globally. Glecaprevir/pibrentasvir is a widely used treatment and has recently been approved for an 8-week regimen for treatment-naïve patients with compensated cirrhosis in Europe and the USA, who would pr...

Descripción completa

Detalles Bibliográficos
Autores principales: Lampertico, Pietro, Mauss, Stefan, Persico, Marcello, Barclay, Stephen T., Marx, Steven, Lohmann, Kristina, Bondin, Mark, Zhang, ZhenZhen, Marra, Fiona, Belperio, Pamela S., Wedemeyer, Heiner, Flamm, Steven
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Healthcare 2020
Materias:
Brief Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7444399/
https://www.ncbi.nlm.nih.gov/pubmed/32754824
http://dx.doi.org/10.1007/s12325-020-01449-0

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7444399/
https://www.ncbi.nlm.nih.gov/pubmed/32754824
http://dx.doi.org/10.1007/s12325-020-01449-0

Ejemplares similares